Travere Therapeutics, Inc. granted inducement equity awards covering an aggregate of 41,600 shares of its common stock to six new employees on July 10, 2026. The grants, consisting of inducement stock options and inducement restricted stock units (RSUs), were made as an inducement material to the individuals entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

The Compensation Committee of the Board of Directors approved the awards, which are subject to the terms of Travere’s 2018 Equity Incentive Plan but were granted outside of it. The aggregate grants include inducement stock options to purchase 18,000 shares and inducement RSUs covering 23,600 shares.

Grant Details

The stock options have an exercise price of $56.59 per share, representing the closing price of Travere’s common stock on the grant date. These non-qualified stock options have a 10-year term and vest over four years. Vesting commences with 25% of the shares vesting on the one-year anniversary of the grant date, while the remaining 75% vest in equal monthly installments over the subsequent 36 months, subject to continued service.

The RSUs also vest over four years, with 25% of the shares vesting on each anniversary of the grant date. These vesting schedules are contingent upon the new employees maintaining their service relationship with Travere through the applicable vesting dates.

Breakdown of Awards

Guggenheim analyst Vamil Divan has maintained a Buy rating on Travere Therapeutics (NASDAQ: TVTX) while raising the stock's price target to $65 from $56. The adjustment reflects an updated valuation outlook for the biopharmaceutical company. Wedbush analyst Laura Chico also recently maintained an Outperform rating on the stock, raising the target to $61 from $55.

The revised targets suggest potential upside from current trading levels, reinforcing the positive stance on the company's prospects. Travere Therapeutics focuses on the development and commercialization of therapies for rare diseases.

Both firms cite the company's continued progress in its therapeutic pipeline as a key driver for the revised outlook.